Here's just a small sampling of the research we are actively pursuing in the lab

Understanding the role of EGFL7 in Aml

We were the first to describe a role for EGFL7 in AML. EGFL7 is a secreted protein and we demonstrated that increased expression of EGFL7 correlates with an shorter overall survival in patients with AML.

Normal hematopoietic stem cell Biology

We are investigating the use of novel recombinant proteins to expand hematopoietic stem cells. With the generation of CRISPR genome editing technologies, we hope to be able to more efficiently culture HSCs in vitro for their use in novel cellular therapies

Developing novel immunotherapies to use in combination with fda-approved drugs in amL

We hope to use anti-EGFL7 therapies in combination with recently approved FLT3 (Gilteritinib) and BCL2 (Venetoclax) inhibitors for patients with AML.